The evolving burden of type 2 diabetes mellitus in Asia, 1990–2023: A Global Burden of Disease Study 2023
Die sich wandelnde Belastung durch Typ-2-Diabetes mellitus in Asien, 1990–2023: Global Burden of Disease Study 2023
Diabetic Medicine · 31.10.2026
DOI: 10.1111/dme.70421 ↗Auf einen Blick
Die Belastung durch Typ-2-Diabetes mellitus nahm in den meisten Regionen Asiens zu. Am stärksten stiegen Prävalenz- und DALY-Raten in Südasien.
Fragestellung
Wie entwickelten sich Trends, regionale Unterschiede und risikobedingte Krankheitslasten von Typ-2-Diabetes in Asien von 1990 bis 2023?
Methode
Analyse der GBD-2023-Daten zu 34 Ländern und 5 Regionen Asiens von 1990 bis 2023; Auswertung von ASPR und ASDR mit 95 %-Unsicherheitsintervallen.
Ergebnisse
In Südasien stiegen ASPR und ASDR am stärksten (ASPR-TPC 66,53 [95 %-UI 61,77 bis 71,77]; ASDR-TPC 75,59 [35,99 bis 123,99] pro 100.000). Im High-income Asia Pacific sank die ASDR leicht (TPC −2,42 [−8,55 bis 3,95]).
Schlussfolgerung der Autor:innen
Die Ergebnisse liefern aktuelle regionale Einblicke in die heterogene Epidemiologie von Typ-2-Diabetes in Asien und können gezielte Präventions- und Kontrollstrategien informieren.
Kernaussagen
- Belastung stieg in den meisten Regionen Asiens
- Südasien zeigte die stärksten Zunahmen
- Feinstaub war in allen Regionen der führende Risikofaktor
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Diabetic Medicine, online erschienen am 31.10.2026. Verfasst von Yujung Lee und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Korean Medicine, Kyung Hee University College of Korean Medicine, Seoul, South Korea. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Science and ICT, South Korea, Ministry of Health & Welfare, Republic of Korea.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Asia accounts for over half of the global prevalence of type 2 diabetes mellitus (T2DM), yet subregional evidence remains limited. We assessed trends, regional disparities and risk‐attributable burdens across Asia from 1990 to 2023.
Methods
We analysed the burden of T2DM across 34 countries and five regions across Asia, including Central, East, South and Southeast Asia and the high‐income Asia Pacific region, using the Global Burden of Disease Study (GBD) 2023 from 1990 to 2023. T2DM was defined as a metabolic disorder characterised by insulin resistance and persistent hyperglycemia and was identified using ICD‐10 codes E11–E11.1 and E11.3–E11.9. Age‐standardised prevalence rate (ASPR) and disability‐adjusted life year (DALY) rate (ASDR) with 95% uncertainty intervals (UIs) per 100,000 population were evaluated, and total percent changes (TPC) over the study period were calculated. Analyses were stratified by age group, sex and Socio‐demographic Index (SDI). Additionally, we assessed the burden attributable to established risk factors for T2DM.
Results
ASPRs and ASDRs of T2DM increased across most Asian regions, with the largest increase exhibited in South Asia (ASPR TPC, 66.53 [95% UI, 61.77 to 71.77]; ASDR TPC, 75.59 [35.99 to 123.99] per 100,000 population). In contrast, High‐income Asia Pacific showed a declining trend of ASDR (TPC, −2.42 [95% UI, −8.55 to 3.95]) per 100,000 population in 2023. Age‐specific incidence rates generally peaked at 55–59 years in most Asian regions; however, East Asian males showed a distinct early peak at 20–24 years (509.61 [95% UI, 399.38 to 615.84] per 100,000 population). Particulate matter pollution was the leading attributable risk factor in all Asian regions. However, a diet low in fruits was the leading contributor in South Asia (157.12 [95% UI, 27.26 to 277.06] per 100,000 population), whereas processed meat consumption increased across most Asian regions, particularly in Central Asia. In most Asian countries, ASPRs increased with SDI, whereas ASDRs declined, although several South Asian countries showed disproportionately high prevalence for their SDI levels.
Conclusions
Our findings provide updated regional insights into the heterogeneous epidemiology of T2DM in Asia and may inform targeted prevention and control strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Korean Medicine, Kyung Hee University College of Korean Medicine, Seoul, South Korea.
- Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
- Department of Precision Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.
- Department of Medicine, Korea University College of Medicine, Seoul, South Korea.
- Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.
- Department of Neurology, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
ORCID-Profile: Dong Keon Yon
Förderung
- Ministry of Science and ICT, South Korea
- Ministry of Health & Welfare, Republic of Korea
Zitieren
APA
Lee, Y., Yoo, H., Kim, H., Kim, D. Y., Shin, H., Yon, H., Oh, J., Woo, H. G., López-Gil, J. F., Smith, L., Woo, S., Park, J., & Yon, D. K. (2026). The evolving burden of type 2 diabetes mellitus in Asia, 1990–2023: A Global Burden of Disease Study 2023. Diabetic Medicine. https://doi.org/10.1111/dme.70421
Vancouver
Lee Y, Yoo H, Kim H, Kim DY, Shin H, Yon H, et al. The evolving burden of type 2 diabetes mellitus in Asia, 1990–2023: A Global Burden of Disease Study 2023. Diabetic Medicine. 2026. doi:10.1111/dme.70421
BibTeX
@article{Lee2026,
author = {Lee, Yujung and Yoo, Hyunyi and Kim, Hyunjee and Kim, Dain Y and Shin, Hyoin and Yon, Hyunju and Oh, Jeongseon and Woo, Ho Geol and López-Gil, José Francisco and Smith, Lee and Woo, Selin and Park, Jaeyu and Yon, Dong Keon},
title = {The evolving burden of type 2 diabetes mellitus in Asia, 1990–2023: A Global Burden of Disease Study 2023},
journal = {Diabetic Medicine},
year = {2026},
doi = {10.1111/dme.70421}
}
EUVIMED